tiprankstipranks
Trending News
More News >

Halozyme raises FY25 non-GAAP EPS view to $5.30-$5.70 from $4.95-$5.35

Raises FY25 revenue view to $1.200B-$1.280B from $1.150B-$1.225B. Consensus is for FY25 EPS $5.00 and for revenue $1.19B. Raises FY25 adjusted EBITDA view to $790M-$840M from $755M-$805M.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue